At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Oligometastatic Non-small Cell Lung Cancer (NSCLC). Completed, enrolled 51 participants across 1 site.
Detailed Summary
The main purpose of this study is to see how well the experimental drug pembrolizumab (MK-3475) works in people with oligometastatic NSCLC who have already had treatment for their disease. All patients will receive 200 mg of pembrolizumab intravenously on Day 1 of each 21-day cycle. Patients will receive the study drug for up to 8 cycles, and then if their disease is doing well and the study doctor thinks they will benefit patients may receive pembrolizumab for up to 8 more cycles.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 2014
Enrollment StartJan 2015
Primary CompletionSep 2018
Study CompletionDec 2022
TodayJul 2026
First PostedDec 12, 2014
Enrollment StartJan 21, 2015
Primary CompletionSep 30, 2018
Study CompletionDec 1, 2022
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 11.6 years ago
Interventions
Pembrolizumabdrug